A Research Study on How a Dose of NNC0662-0419 Works in Japanese, Chinese and Non-Asian Participants Living With Overweight or Obesity

Launched by NOVO NORDISK A/S · Jul 28, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medicine called NNC0662-0419 to see how it works in people who are overweight or have obesity. The main goal is to understand how much of the medicine stays in the blood after one single injection under the skin. The study also wants to find out if the medicine is safe and well-tolerated, meaning whether it causes any side effects or problems. This medicine is still being tested and is not available by prescription. The whole study will last up to two months.

People who might be eligible to join are adults aged 18 to 55 who identify as Japanese, Chinese, or non-Asian, with both parents from the same background. Participants should have a body mass index (BMI) between 24.0 and 34.9, which means they are overweight or mildly obese due to extra body fat. Before joining, they will have a health check to make sure the medicine is safe for them. If accepted, participants will receive one dose of the medicine during the study and will be closely monitored for any side effects. It’s important to know that not everyone can join, especially if they have certain heart conditions, blood sugar issues, or allergies to the study medicine.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female (sex at birth) Japanese, Chinese or non-Asian participants (all self-reported).
• • For Japanese participants: both parents of Japanese descent.
• • For Chinese participants: both parents of Chinese descent.
• • For non-Asian participants: both parents of non-Asian descent (non-Asian is defined as of countries outside of Asia).
• • Age 18-55 years (both inclusive) at the time of signing the informed consent.
• • Body mass index (BMI) between 24.0 and 34.9 kilogram per square meter (kg/m\^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
• • Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.
• Exclusion Criteria:
• • Known a\* or suspected hypersensitivity to study intervention(s) or related products.
• • Any disorder, unwillingness or inability which in the investigator's opinion, might jeopardise the participant's safety or compliance with the protocol.
• • 2nd or 3rd degree atrioventricular-block, prolongation of the QRS complex over 120 millisecond (msec), or of the corrected QT interval by Fridericia (QTcF) calculation over 450 msec (females) or 430 msec (males), or any other clinically significant abnormal electrocardiogram (ECG) results as judged by the investigator, at screening.
• • Glycated haemoglobin (HbA1c) greater than or equal to \>= 6.5percent (%) (48 millimoles per liter \[mmol/mol\]) at screening.
• • Calcitonin \>= 50 nanogram per liter (ng/L) at screening. a\* - As declared by the participant or reported in the medical records.